Pharmaceuticals, Biotechnology and Life Sciences
The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology Medicago’s platform…
Amunix Pharmaceuticals, a tumor cancer-focused biopharmaceutical company has completed $73 million Series A financing round.
mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical…
First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD…
Clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in the San Francisco Bay Area.
Merck said Monday that it iwll, through a subsidiary, initiate a tender offer to acquire all outstanding shares of ArQule for nearly $2.7 billion, or for $20 per share in cash.
Equillium got U.S. FDA’s Fast Track designation for itolizumab for the treatment of lupus nephritis, after startign the phase 1 study of itolizumab in patients with lupus and lupus nephritis in September 2019.
Inceptua Medicines Access, a business unit of the Inceptua Group, has announced the collaboration with Onconova Therapeutics to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
Actinium Pharmaceuticals is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.
Novartis Phase III Palladium clinical trial has met the primary endpoing, as it showed that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function.